Company Description
EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases.
The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.
Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME).
The company’s pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases.
The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018.
EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
| Country | United States |
| Founded | 1987 |
| IPO Date | Jan 27, 2005 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Jay Duker |
Contact Details
Address: 480 Pleasant Street, Suite A-210 Watertown, Massachusetts 02472 United States | |
| Phone | 617 926 5000 |
| Website | eyepointpharma.com |
Stock Details
| Ticker Symbol | EYPT |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001314102 |
| CUSIP Number | 30233G209 |
| ISIN Number | US30233G2093 |
| Employer ID | 26-2774444 |
| SIC Code | 3826 |
Key Executives
| Name | Position |
|---|---|
| Dr. Jay S. Duker M.D. | President, Chief Executive Officer and Director |
| George O. Elston | Executive Vice President and Chief Financial Officer |
| Dr. John B. Landis M.S., Ph.D. | Interim Head of Research & Development and Director |
| Michael J. Maciocio | Senior Vice President of Manufacturing and Operations |
| Ron I. Honig Esq. | Chief Legal Officer and Company Secretary |
| Jennifer Leonard | Chief People Officer and Senior Vice President of IT |
| David Scott Jones M.A. | Senior Vice President and Chief Commercial Officer |
| Michael Pine | Chief Business Officer |
| Isabelle Lefebvre | Chief Regulatory Officer |
| Dr. Marcia Sellos-Moura Ph.D. | Senior Vice President and Head of Development and Program Management |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 24, 2024 | 8-K | Current Report |
| Oct 23, 2024 | 144 | Filing |
| Oct 22, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Oct 15, 2024 | 144 | Filing |
| Sep 4, 2024 | 8-K | Current Report |
| Aug 16, 2024 | EFFECT | Notice of Effectiveness |
| Aug 14, 2024 | UPLOAD | Filing |
| Aug 8, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Aug 8, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Aug 8, 2024 | 10-Q | Quarterly Report |